Compare Gilead Sciences, Inc. (GILD) vs Global X Lithium & Battery Tech ETF (LIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Global X Lithium & Battery Tech ETF — how do they compare? Gilead Sciences, Inc. trades at $135.69 (market cap $163.51B), while Global X Lithium & Battery Tech ETF trades at $68.62. The key difference: Gilead Sciences, Inc. pays a 2.49% dividend while Global X Lithium & Battery Tech ETF pays none. Which is the better fit depends on your goals.
| GILD | LIT | |
|---|---|---|
Market Cap | $163.51B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $155.80 | $91.62 |
52-Week Low | $108.22 | $39.73 |
Enterprise Value | $178.05B | — |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
Global X Lithium & Battery Tech ETF (LIT) trades at $68.72, down 4.0% over 24 hours amid bearish technical signals. The ETF has demonstrated strong momentum with a 125% return from last year's lows, driven by accelerating EV adoption and lithium market recovery. Recent news highlights expanding global EV sales, China's ambitious 30% NEV fleet target by 2030, and ongoing geopolitical influences on energy markets. Technical indicators show oversold conditions with RSI levels below 30, while moving averages remain bearish.
The outlook for LIT remains tied to lithium demand growth from EVs, energy storage, and semiconductors. Investment opportunities exist in the ongoing electrification trend and supply chain reshoring, while risks include Chinese export controls, potential EV demand volatility, and competitive pressures from Chinese automakers entering global markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Global X Lithium & Battery Tech ETF
LIT invests in the full lithium cycle, from mining and refining to battery production and EV manufacturing. It tracks the Solactive Global Lithium Index, with top holdings including Rio Tinto, Albemarle, and Tesla, as well as major battery makers like Samsung SDI.
Read more on LIT →
